Table 1 Baseline characteristics of patients with nail psoriasis randomized to guselkumab or adalimumab

Randomized patients

n = 108

n = 63

n = 101

n = 65

n = 67

Age, years

  Mean ± S.D

44.4 ± 12.3

44.6 ± 10.9

42.2 ± 10.3

43.8 ± 11.3

44.1 ± 11.0

Men, n (%)

76 (70.4)

52 (82.5)

76 (75.2)

41 (63.1)

47 (70.1)

Race, n (%)

  White

91 (84.3)

50 (79.4)

90 (89.1)

55 (84.6)

59 (88.1)

  Asian

14 (13.0)

9 (14.3)

10 (9.9)

8 (12.3)

7 (10.4)

  Black

0

2 (3.2)

1 (1.0)

1 (1.5)

1 (1.5)

BMI, kg/m²

  Mean ± S.D

29.9 ± 5.8

31.6 ± 6.5

29.3 ± 6.2

28.9 ± 6.1

31.3 ± 6.2

Smoking status, n (%)

  Current smoker

36 (33.3)

15 (23.8)

39 (38.6)

18 (27.7)

32 (47.8)

  Former smoker

21 (19.4)

13 (20.6)

20 (19.8)

14 (21.5)

15 (22.4)

  Never smoker

51 (47.2)

35 (55.6)

42 (41.6)

33 (50.8)

20 (29.9)

Duration of psoriasis, years

  Mean ± S.D

19.6 ± 12.4

20.1 ± 11.8

17.8 ± 11.7

18.6 ± 12.1

18.3 ± 12.2

BSA involvement, %

  Mean ± S.D

28.4 ± 16.5

30.8 ± 19.7

29.0 ± 15.7

30.4 ± 15.7

26.3 ± 16.9

IGA score, 0–4, n (%)

  Moderate, 3

85 (78.7)

43 (68.3)

76 (75.2)

56 (86.2)

50 (74.6)

  Severe, 4

23 (21.3)

20 (31.7)

25 (24.8)

9 (13.8)

17 (25.4)

PASI, 0–72

  Mean ± S.D

22.6 ± 8.8

23.1 ± 9.8

23.2 ± 9.0

22.7 ± 8.6

20.1 ± 8.5

 NAPSI, 0–8

n = 108

n = 61

n = 97

n = 62

n = 66

  Mean ± S.D

4.4 ± 1.8

4.9 ± 2.0

5.0 ± 2.1

4.7 ± 1.9

4.2 ± 1.9

 Nail bed score

n = 108

n = 61

n = 97

n = 62

n = 66

  Mean ± S.D

1.9 ± 1.2

2.1 ± 1.3

2.2 ± 1.2

2.1 ± 1.1

2.0 ± 1.0

 Nail matrix score

n = 107

n = 61

n = 97

n = 62

n = 66

  Mean ± S.D

2.5 ± 1.2

2.7 ± 1.2

2.7 ± 1.3

2.6 ± 1.2

2.2 ± 1.4

f-PGA, 0–4, n (%)

  Minimal, 1

18 (16.7)

6 (9.8)

10 (10.2)

5 (8.1)

10 (15.4)

  Mild, 2

37 (34.3)

15 (24.6)

35 (35.7)

23 (37.1)

23 (35.4)

  Moderate, 3

42 (38.9)

30 (49.2)

45 (45.9)

26 (41.9)

30 (46.2)

  Severe, 4

11 (10.2)

10 (16.4)

7 (7.1)

8 (12.9)

2 (3.1)

Psoriatic arthritis, n (%)

21 (19.4)

16 (25.4)

27 (26.7)

17 (26.2)

17 (25.4)

Prior treatments

  Topical agents

102 (94.4)

56 (88.9)

101 (100.0)

62 (95.4)

65 (97.0)

  Phototherapy

67 (62.0)

44 (69.8)

64 (63.4)

35 (53.8)

34 (50.7)

  Conventional systemic agents

60 (55.6)

48 (76.2)

65 (64.4)

40 (61.5)

46 (68.7)

  Biologic agents

23 (21.3)

17 (27.0)

16 (15.8)

10 (15.4)

12 (17.9)

DLQI, 0–30

n = 107

n = 63

n = 101

n = 64

n = 67

  Mean ± S.D

14.3 ± 6.4

16.0 ± 8.0

14.5 ± 6.1

15.2 ± 6.1

15.3 ± 8.0